📣 Notice: Short Maintenance Tonight (May 19th)
Due to increasing user numbers, we’re upgrading our servers this evening. StocksGuide will be unavailable for about 5–10 minutes between 4:00 PM and 5:00 PM (EDT / New York time). Afterwards, you’ll continue to benefit from fast and stable site performance. Thank you for your understanding! Your StocksGuide Team

$9.85
1.86% today
Nasdaq, May 19, 07:46 pm CET
ISIN
US2681582019
Symbol
DVAX

Dynavax Technologies Corporation Stock price

$9.67
-0.98 9.20% 1M
-2.02 17.28% 6M
-3.10 24.28% YTD
-1.61 14.27% 1Y
-0.15 1.53% 3Y
+4.81 98.97% 5Y
-11.33 53.95% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.16 1.68%
ISIN
US2681582019
Symbol
DVAX
Sector
Industry

Key metrics

Market capitalization $1.16b
Enterprise Value $789.95m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 14.62
EV/Sales (TTM) EV/Sales 2.68
P/S ratio (TTM) P/S ratio 3.94
P/B ratio (TTM) P/B ratio 2.25
Revenue growth (TTM) Revenue growth 24.76%
Revenue (TTM) Revenue $294.62m
EBIT (operating result TTM) EBIT $-9.12m
Free Cash Flow (TTM) Free Cash Flow $54.02m
Cash position $661.34m
EPS (TTM) EPS $-0.53
P/E forward negative
P/S forward 3.53
EV/Sales forward 2.40
Short interest 23.63%
Show more

Is Dynavax Technologies Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Dynavax Technologies Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Dynavax Technologies Corporation forecast:

4x Buy
80%
1x Sell
20%

Analyst Opinions

5 Analysts have issued a Dynavax Technologies Corporation forecast:

Buy
80%
Sell
20%

Financial data from Dynavax Technologies Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
295 295
25% 25%
100%
- Direct Costs 52 52
13% 13%
18%
242 242
28% 28%
82%
- Selling and Administrative Expenses 176 176
19% 19%
60%
- Research and Development Expense 67 67
23% 23%
23%
-0.98 -0.98
93% 93%
0%
- Depreciation and Amortization 8.14 8.14
8% 8%
3%
EBIT (Operating Income) EBIT -9.12 -9.12
57% 57%
-3%
Net Profit -60 -60
752% 752%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Dynavax Technologies Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dynavax Technologies Corporation Stock News

Neutral
Business Wire
4 days ago
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today issued a letter to shareholders in connection with its nomination of four highly ...
Neutral
PRNewsWire
7 days ago
Presentation Underscores Deep Track's Value Destructive Plan and Inferior Slate of Director Nominees Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 12, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial-stage biopharmaceutical company developing and commerciali...
Neutral
PRNewsWire
12 days ago
Deep Track's Misleading Investor Presentation Demonstrates its Single-Minded Approach to Abandon Long-Term Value Opportunities in Exchange for Short-Term Return Urges Stockholders to Vote "FOR" All Four Dynavax Director Nominees on the GOLD Proxy Card Today EMERYVILLE, Calif. , May 7, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX) ("Dynavax" or the "Company"), a commercial...
More Dynavax Technologies Corporation News

Company Profile

Dynavax Technologies Corp. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of novel vaccines and immuno-oncology therapeutics. The firm focuses on leveraging the body's innate and adaptive immune responses through toll-like receptor stimulation. It offers products for vaccines, cancer immunotherapy, and immune-mediated diseases. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Berkeley, CA.

Head office United States
CEO Ryan Spencer
Employees 405
Founded 1996
Website www.dynavax.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today